Oryzon Genomics S.A. (BME:ORY)
Spain · Delayed Price · Currency is EUR 2.820
-0.020 (-0.70%)
Aug 27, 2026, 5:35 PM CET
Oryzon Genomics Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 15.41 | 10.93 | 7.36 | 14.19 | 15.7 | 10.62 | |
Revenue Growth | 106.22% | 48.59% | -48.15% | -9.60% | 47.88% | 11.49% |
Cost of Revenue | 0.35 | 0.28 | 0.3 | 0.24 | 0.46 | 0.75 |
Gross Profit | 15.06 | 10.65 | 7.06 | 13.95 | 15.23 | 9.87 |
Selling, General & Admin | 3.88 | 3.79 | 3.55 | 3.61 | 3.57 | 3.67 |
Other Operating Expenses | 17 | 12.44 | 7.86 | 14.75 | 17 | 13.07 |
Operating Expenses | 21 | 16.36 | 11.56 | 18.51 | 20.73 | 16.88 |
Operating Income | -5.94 | -5.71 | -4.5 | -4.56 | -5.5 | -7.01 |
Interest Expense | - | -0 | -0 | -1.89 | -1.12 | -0.46 |
Interest & Investment Income | 0.51 | 0.71 | 0.2 | 0.03 | 0.01 | 0.01 |
Currency Exchange Gain (Loss) | 0.03 | 0.05 | -0.09 | 0.1 | 0.24 | 0.28 |
Other Non Operating Income (Expenses) | -0.61 | -0.65 | -1.17 | 0.2 | -0.2 | 0 |
EBT Excluding Unusual Items | -6.01 | -5.6 | -5.56 | -6.12 | -6.56 | -7.18 |
Gain (Loss) on Sale of Assets | - | - | - | - | - | -0 |
Asset Writedown | -0 | -0 | - | - | - | - |
Other Unusual Items | 0.04 | 0.01 | 0.08 | 0.01 | 0.01 | 0.01 |
Pretax Income | -5.97 | -5.6 | -5.48 | -6.1 | -6.56 | -7.18 |
Income Tax Expense | -3.55 | -2.99 | -1.91 | -2.75 | -2.33 | -2.49 |
Net Income | -2.43 | -2.61 | -3.58 | -3.35 | -4.23 | -4.69 |
Net Income to Common | -2.43 | -2.61 | -3.58 | -3.35 | -4.23 | -4.69 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 78 | 78 | 65 | 61 | 55 | 53 |
Shares Outstanding (Diluted) | 78 | 78 | 65 | 61 | 55 | 53 |
Shares Change | 0.01% | 19.72% | 6.35% | 10.10% | 4.80% | - |
EPS (Basic) | -0.03 | -0.03 | -0.06 | -0.06 | -0.08 | -0.09 |
EPS (Diluted) | -0.03 | -0.03 | -0.06 | -0.06 | -0.08 | -0.09 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -5 | -2.42 | -5.79 | -0.57 | -1.92 | -3.8 |
Free Cash Flow Per Share | -0.06 | -0.03 | -0.09 | -0.01 | -0.04 | -0.07 |
Gross Margin | 97.75% | 97.42% | 95.89% | 98.28% | 97.04% | 92.97% |
Operating Margin | -38.56% | -52.25% | -61.18% | -32.16% | -35.02% | -66.07% |
Profit Margin | -15.76% | -23.83% | -48.62% | -23.63% | -26.96% | -44.15% |
Free Cash Flow Margin | -32.44% | -22.09% | -78.70% | -4.05% | -12.25% | -35.82% |
EBITDA | -5.84 | -5.6 | -4.38 | -4.43 | -5.35 | -6.88 |
EBITDA Margin | -37.91% | -51.19% | -59.47% | -31.24% | -34.08% | -64.81% |
D&A For EBITDA | 0.1 | 0.12 | 0.13 | 0.13 | 0.15 | 0.13 |
EBIT | -5.94 | -5.71 | -4.5 | -4.56 | -5.5 | -7.01 |
EBIT Margin | -38.56% | -52.25% | -61.18% | -32.16% | -35.02% | -66.07% |